Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Vyndaqel (tafamidis) Disease area(s): Cardiovascular/Rare disease Manufacturer(s): Pfizer 2024 Sales (USD): $5.45 billion Why it sold so well: In 2024, Pfizers Vyndaqel family (including Vyndaqel, Vyndamax and Vynmac) achieved significant sales growth, with global revenues increasing by 60% year-over-year
Introduction GLP-1 agonists are highly effective tools for weight loss and metabolic management, yet many users face nausea as a frustrating side effect
With the rise of GLP-1 drug usage, there is an increasing demand for healthier, lower-calorie foods
Mean platelet volume and coronary plaque vulnerability: an optical coherence tomography study in patients with non-ST-elevation acute coronary syndrome
Hers focuses on brand-name access through a simple cash-pay membership, while Josie was created for women navigating hormonal changes in midlife
